Logos Global Management’s Aclaris Therapeutics ACRS Stock Holding History

Logos Global Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.88M	Sell	500,000 -100,000	-17%	-$337K	0.09%	61
2025 Q4	$1.81M	Sell	600,000 -900,000	-60%	-$2.27M	0.11%	64
2025 Q3	$2.85M	Sell	1,500,000 -350,000	-19%	-$610K	0.26%	52
2025 Q2	$2.63M	Sell	1,850,000 -372,222	-17%	-$504K	0.29%	47
2025 Q1	$3.4M	Hold	2,222,222	–	–	0.6%	29
2024 Q4	$5.51M	Buy	+2,222,222	New	+$5.53M	0.64%	35
2023 Q3	–	Sell	-525,000	Closed	-$5.44M	–	58
2023 Q2	$5.44M	Buy	+525,000	New	+$4.75M	0.74%	38
2021 Q3	–	Sell	-675,000	Closed	-$11.9M	–	58
2021 Q2	$11.9M	Buy	+675,000	New	+$15.3M	1%	30

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Logos Global Management's ACRS Position: Q1 2026 in Review

Logos Global Management reduced its Aclaris Therapeutics (ACRS) stake by 17% in Q1 2026, selling an estimated $337K and leaving 500,000 shares worth $1.88M. The position accounts for 0.09% of the portfolio, ranked #61.

Logos Global Management first reported a position in ACRS in Q2 2021 and has held it in 8 quarters since. The position peaked at $11.9M in Q2 2021. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

Logos Global Management held 500,000 shares of Aclaris Therapeutics worth $1.88M as of Q1 2026.
Logos Global Management sold 100,000 Aclaris Therapeutics shares in Q1 2026, an estimated $337K.
Aclaris Therapeutics made up 0.09% of Logos Global Management's portfolio in Q1 2026, its #61 holding.
Logos Global Management first reported a position in Aclaris Therapeutics in Q2 2021 and has held it in 8 quarters since.
Logos Global Management's Aclaris Therapeutics position peaked at $11.9M in Q2 2021.
136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Logos Global Management's 13F filing for Q1 2026, filed 15 May 2026.